
Rafael Banares

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6156870/publications.pdf Version: 2024-02-01



RAFAFI RANADES

#	Article	IF	CITATIONS
1	Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial. Hepatology, 2013, 57, 1153-1162.	7.3	452
2	Clinical events after transjugular intrahepatic portosystemic shunt: Correlation with hemodynamic findings. Gastroenterology, 1998, 114, 1296-1303.	1.3	431
3	Efficacy and Safety of Anticoagulation on Patients With Cirrhosis and Portal Vein Thrombosis. Clinical Gastroenterology and Hepatology, 2012, 10, 776-783.	4.4	407
4	Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: A meta-analysis. Hepatology, 2002, 35, 609-615.	7.3	401
5	β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, The, 2019, 393, 1597-1608.	13.7	375
6	Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial. Gastroenterology, 2009, 136, 1651-1658.	1.3	372
7	A Histologic Scoring System for Prognosis of Patients With AlcoholicÂHepatitis. Gastroenterology, 2014, 146, 1231-1239.e6.	1.3	353
8	Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. Journal of Hepatology, 2008, 48, 229-236.	3.7	284
9	A New Scoring System for Prognostic Stratification of Patients With Alcoholic Hepatitis. American Journal of Gastroenterology, 2008, 103, 2747-2756.	0.4	268
10	Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. Hepatology, 2005, 42, 793-801.	7.3	213
11	Effects of All-Oral Anti-Viral Therapy on HVPG and SystemicÂHemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. Gastroenterology, 2017, 153, 1273-1283.e1.	1.3	210
12	Multicenter Randomized Controlled Trial of Terlipressin Versus Sclerotherapy in the Treatment of Acute Variceal Bleeding: The TEST Study. Hepatology, 2000, 32, 471-476.	7.3	196
13	TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: A randomized controlled trial. Hepatology, 2002, 35, 385-392.	7.3	195
14	Portal Hypertension–Related Complications After Acute Portal Vein Thrombosis: Impact of Early Anticoagulation. Clinical Gastroenterology and Hepatology, 2008, 6, 1412-1417.	4.4	175
15	Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study. Hepatology, 1995, 21, 674-679.	7.3	171
16	Meta-analysis: Combination Endoscopic and Drug Therapy to Prevent Variceal Rebleeding in Cirrhosis. Annals of Internal Medicine, 2008, 149, 109.	3.9	169
17	Response to steroids in <i>de novo</i> autoimmune hepatitis after liver transplantation. Hepatology, 2002, 35, 349-356.	7.3	164
18	Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology, 2001, 121, 382-388.	1.3	159

#	Article	IF	CITATIONS
19	Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha ₁ -adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology, 1999, 30, 79-83.	7.3	158
20	A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. Journal of Hepatology, 2005, 43, 990-996.	3.7	151
21	Antiviral Therapy Decreases Hepatic Venous Pressure Gradient in Patients with Chronic Hepatitis C and Advanced Fibrosis. American Journal of Gastroenterology, 2006, 101, 2269-2274.	0.4	150
22	Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: A double-blind RCT. Hepatology, 2003, 37, 1260-1266.	7.3	149
23	Development of hyperdynamic circulation and response to βâ€blockers in compensated cirrhosis with portal hypertension. Hepatology, 2016, 63, 197-206.	7.3	143
24	Value of the Hepatic Venous Pressure Gradient to Monitor Drug Therapy for Portal Hypertension: A Meta-Analysis. American Journal of Gastroenterology, 2007, 102, 1116-1126.	0.4	137
25	Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding. Journal of Hepatology, 2001, 35, 712-718.	3.7	135
26	Continuous prazosin administration in cirrhotic patients: Effects on portal hemodynamics and on liver and renal function. Gastroenterology, 1995, 109, 1257-1265.	1.3	130
27	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology, 2002, 36, 1367-1373.	7.3	121
28	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology, 2002, 36, 1367-1373.	7.3	113
29	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. Journal of Hepatology, 2020, 73, 1082-1091.	3.7	112
30	Impact of anticoagulation on upperâ€gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. Hepatology, 2015, 62, 575-583.	7.3	105
31	Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. Journal of Hepatology, 2020, 73, 1415-1424.	3.7	104
32	Comparison of transjugular intrahepatic portosystemic shunt dysfunction in PTFE-covered stent-grafts versus bare stents. European Journal of Radiology, 2005, 55, 120-124.	2.6	95
33	Randomized controlled trial of sclerotherapy versus somatostatin infusion in the prevention of early rebleeding following acute variceal hemorrhage in patients with cirrhosis. Journal of Hepatology, 1998, 29, 779-788.	3.7	94
34	Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver International, 2010, 30, 1137-1142.	3.9	87
35	Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. Liver International, 2003, 23, 39-43.	3.9	85
36	The heart in liver transplantation. Journal of Hepatology, 2011, 54, 810-822.	3.7	84

#	Article	IF	CITATIONS
37	Cardiac Dysfunction During Liver Transplantation: Incidence and Preoperative Predictors. Transplantation, 2008, 85, 1766-1772.	1.0	77
38	Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. Clinical Gastroenterology and Hepatology, 2020, 18, 313-327.e6.	4.4	74
39	Hemodynamic effects of α-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension. Hepatology, 1994, 20, 611-617.	7.3	64
40	Oral probiotic <scp>VSL</scp> #3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. Liver International, 2014, 34, 1504-1512.	3.9	61
41	Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. Clinical Gastroenterology and Hepatology, 2015, 13, 1846-1853.e1.	4.4	60
42	Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites. Journal of Hepatology, 2020, 73, 1404-1414.	3.7	58
43	Oral administration of clonidine in patients with alcoholic cirrhosis. Gastroenterology, 1992, 102, 248-254.	1.3	57
44	Risk factors for developing <i>de novo</i> autoimmune hepatitis associated with anti-glutathione S-transferase T1 antibodies after liver transplantation. Liver Transplantation, 2009, 15, 530-539.	2.4	52
45	Use of Everolimus as a Rescue Immunosuppressive Therapy in Liver Transplant Patients With Neoplasms. Transplantation, 2007, 84, 786-791.	1.0	48
46	Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. Hepatology, 2013, 58, 2079-2088.	7.3	48
47	Early noninvasive measurement of the indocyanine green plasma disappearance rate accurately predicts early graft dysfunction and mortality after deceased donor liver transplantation. Liver Transplantation, 2009, 15, 1247-1253.	2.4	46
48	Left ventricular systolic function is associated with sympathetic nervous activity and markers of inflammation in cirrhosis. Hepatology, 2017, 65, 2019-2030.	7.3	43
49	Randomized Controlled Trial of Aspiration Needle versus Automated Biopsy Device for Transjugular Liver Biopsy. Journal of Vascular and Interventional Radiology, 2001, 12, 583-587.	0.5	40
50	Antibodies Against Glutathione S-Transferase T1 (GSTT1) in Patients With GSTT1 Null Genotype as Prognostic Marker: Long-Term Follow-Up After Liver Transplantation. Transplantation, 2007, 83, 1126-1129.	1.0	38
51	Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis. Scandinavian Journal of Gastroenterology, 2013, 48, 487-495.	1.5	38
52	Prevalence of portal hypertensive duodenopathy in cirrhosis: clinical and haemodynamic features. European Journal of Gastroenterology and Hepatology, 2006, 18, 649-653.	1.6	35
53	Patients with cirrhosis and bare-stent TIPS may have increased risk of hepatocellular carcinoma. Hepatology, 2005, 41, 566-571.	7.3	32
54	Comparison of MELD, HVPG, and their changes to predict clinically relevant endpoints in cirrhosis. Scandinavian Journal of Gastroenterology, 2012, 47, 204-211.	1.5	29

#	Article	IF	CITATIONS
55	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. Journal of Hepatology, 2021, 75, 342-350.	3.7	28
56	Extravascular Lung Water and Pulmonary Vascular Permeability Index Measured at the End of Surgery Are Independent Predictors of Prolonged Mechanical Ventilation in Patients Undergoing Liver Transplantation. Anesthesia and Analgesia, 2015, 121, 736-745.	2.2	25
57	The extent of the collateral circulation influences the postprandial increase in portal pressure in patients with cirrhosis. Gut, 2007, 56, 259-264.	12.1	24
58	Molecular Adsorbent Recirculating System and Bioartificial Devices for Liver Failure. Clinics in Liver Disease, 2014, 18, 945-956.	2.1	24
59	Early Measurement of Indocyanine Green Clearance Accurately Predicts Short-Term Outcomes After Liver Transplantation. Transplantation, 2016, 100, 613-620.	1.0	24
60	Persistence of Clinically Significant Portal Hypertension After Eradication of Hepatitis C Virus in Patients With Advanced Cirrhosis. Clinical Infectious Diseases, 2020, 71, 2726-2729.	5.8	23
61	Serum angiopoietin-2 level as a predictor of tumor invasiveness in patients with hepatocellular carcinoma. Scandinavian Journal of Gastroenterology, 2013, 48, 334-343.	1.5	22
62	Enfermedades vasculares del hÃgado. GuÃas ClÃnicas de la Sociedad Catalana de DigestologÃa y de la Asociación Española para el Estudio del HÃgado. GastroenterologÃa Y HepatologÃa, 2017, 40, 538-580.	0.5	20
63	Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients. World Journal of Transplantation, 2014, 4, 133.	1.6	18
64	Serum levels of soluble vascular cell adhesion molecule are related to hyperdynamic circulation in patients with liver cirrhosis. Liver International, 2008, 28, 1129-1135.	3.9	16
65	Molecular Profiling of Decompensated Cirrhosis by a Novel MicroRNA Signature. Hepatology Communications, 2021, 5, 309-322.	4.3	13
66	Enfermedad hepática por alcohol. GuÃas de práctica clÃnica. Documento de consenso auspiciado por la AEEH. GastroenterologÃa Y HepatologÃa, 2019, 42, 657-676.	0.5	12
67	Characteristic haemodynamic changes of cirrhosis may influence the diagnosis of portopulmonary hypertension. Liver International, 2015, 35, 353-361.	3.9	11
68	Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver. GastroenterologÃa Y HepatologAa (English Edition), 2017, 40, 538-580.	0.1	10
69	De novo autoimmune hepatitis after liver transplantation: A focus on glutathione Sâ€ŧransferase theta 1. Liver Transplantation, 2017, 23, 75-85.	2.4	7
70	Current Clinical Status of the Extracorporeal Liver Support Devices. , 2015, , 1463-1487.		4
71	Does interferon improve portal hypertension?. Journal of Antimicrobial Chemotherapy, 2006, 58, 7-12.	3.0	3
72	Prognostic Markers in Patients Who Have Recovered from an Acute Variceal Bleeding: Role of HVPG Measurement. Disease Markers, 2011, 31, 165-169.	1.3	3

#	Article	IF	CITATIONS
73	Serum level of soluble vascular cell adhesion molecule in patients with hepatocellular carcinoma and its association with severity of liver disease. Annals of Hepatology, 2013, 12, 236-247.	1.5	3
74	Effect of Eradication of HCV on Hepatic Venous Pressure Gradient in HIV-Infected Patients With Compensated HCV-Related Cirrhosis. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, e142-e144.	2.1	3
75	Intraoperative Troponin Elevation in Liver Transplantation Is Independently Associated With Mortality: A Prospective Observational Study. Liver Transplantation, 2020, 26, 681-692.	2.4	3
76	Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis. JHEP Reports, 2021, 3, 100368.	4.9	3
77	Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). GastroenterologAa Y HepatologAa, 2022, 45, 724-734.	0.5	3
78	Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis. BMC Infectious Diseases, 2018, 18, 170.	2.9	2
79	Reply:. Hepatology, 2005, 42, 236-237.	7.3	1
80	Liver Support With Albumin Dialysis Reduces Hepatitis C Virus Viremia and Facilitates Antiviral Treatment of Severe Hepatitis C Virus Recurrence After Liver Transplantation. Therapeutic Apheresis and Dialysis, 2016, 20, 189-196.	0.9	1
81	Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH. GastroenterologÃa Y HepatologÃa (English Edition), 2019, 42, 657-676.	0.1	1
82	It takes two "eyes―to see in depth. Journal of Hepatology, 2019, 70, 790-791.	3.7	1
83	A simple nomogram identifies patients with refractory ascites with worse outcome after transjugular intrahepatic portosystemic shunt. European Journal of Gastroenterology and Hepatology, 2021, 33, e587-e593.	1.6	1
84	Extracorporeal Artificial Liver Support Systems. , 2011, , 501-519.		1
85	Reply:. Hepatology, 2002, 36, 1024-1025.	7.3	Ο
86	Reply to: "Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?― Journal of Hepatology, 2020, 73, 977-979.	3.7	0